Stocks · News reference

8-K filing — LISATA THERAPEUTICS, INC. (LSTA)

Jul 24, 2026, 4:15 PMSEC EDGAR

Filed: 2026-07-24 AccNo: 0001140361-26-029541 Size: 157 KB Item 1.02: Termination of a Material Definitive Agreement Item 8.01: Other Events

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: edgar
Observed: Jul 24, 2026, 4:15 PM
Checked: Jul 24, 2026, 4:15 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 4, 2026, 6:27 PMBenzinga Newsdesk
Lisata shares are trading higher after the company announced it is pursuing damages through litigation over Kuva’s breached merger agreement, reviewing strategic alternatives, and cutting costs with a major workforce reduction to preserve cash.
LSTA
BenzingaAug 4, 2026, 11:14 AMBenzinga Newsdesk
Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees
Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking,
LSTA
BenzingaJul 24, 2026, 5:54 PMBenzinga Newsdesk
Lisata Therapeutics shares are trading lower after the company announced it has terminated its merger agreement with Kuva Labs.
LSTA
BenzingaJul 24, 2026, 4:20 PMBenzinga Newsdesk
Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale
https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm
LSTA